Liver Fibrosis Determination

Michelle Lai; Nezam H Afdhal

doi:10.1016/j.gtc.2019.02.002

Liver Fibrosis Determination

Gastroenterol Clin North Am. 2019 Jun;48(2):281-289. doi: 10.1016/j.gtc.2019.02.002. Epub 2019 Apr 1.

Authors

Michelle Lai¹, Nezam H Afdhal²

Affiliations

¹ Department of Medicine, Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Suite 4A, Boston, MA 02215, USA. Electronic address: mlai@bidmc.harvard.edu.
² Department of Medicine, Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Suite 4A, Boston, MA 02215, USA.

PMID: 31046975
DOI: 10.1016/j.gtc.2019.02.002

Abstract

All chronic liver disease can lead to liver fibrosis. Assessment of the severity of liver fibrosis is central to making treatment and management decisions. Liver biopsy, the gold standard for liver fibrosis assessment, is invasive and carries risks of complications and sampling errors. The use of noninvasive elastography-based radiologic methods of liver fibrosis determination is limited to centers that have the capabilities. Laboratory liver fibrosis determinations, both general clinical scoring systems and combination biomarker panels, are accessible to a wider population of clinicians for identifying patients at low risk of advanced fibrosis who do not need liver biopsies.

Keywords: APRI; ELF; FIB-4; Fibrosure; Fibrotest; Hepascore; Liver fibrosis; NAFLD fibrosis score.

Publication types

Review

MeSH terms

Biomarkers / analysis
Biopsy
Chronic Disease
Clinical Laboratory Techniques*
Female
Humans
Liver Cirrhosis / diagnosis*
Liver Cirrhosis / diagnostic imaging
Liver Cirrhosis / etiology
Liver Diseases / complications
Male
Radiography
Risk

Substances

Biomarkers